Glaukos (GKOS) Competitors $88.01 -0.48 (-0.54%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$88.00 -0.01 (-0.01%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GKOS vs. ZBH, SNN, SOLV, PEN, STVN, IRTC, BLCO, TMDX, SLNO, and INSPShould you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Glaukos vs. Its Competitors Zimmer Biomet Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Inspire Medical Systems Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Do insiders and institutionals hold more shares of ZBH or GKOS? 88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 5.8% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, ZBH or GKOS? Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimmer Biomet$7.68B2.53$903.70M$4.5221.75Glaukos$383.48M13.16-$146.37M-$1.65-53.34 Do analysts rate ZBH or GKOS? Zimmer Biomet presently has a consensus target price of $111.65, suggesting a potential upside of 13.57%. Glaukos has a consensus target price of $127.42, suggesting a potential upside of 44.78%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Zimmer Biomet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 1 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.42Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85 Does the media prefer ZBH or GKOS? In the previous week, Zimmer Biomet had 10 more articles in the media than Glaukos. MarketBeat recorded 22 mentions for Zimmer Biomet and 12 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.17 beat Glaukos' score of 0.63 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 18 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZBH or GKOS more profitable? Zimmer Biomet has a net margin of 11.86% compared to Glaukos' net margin of -21.43%. Zimmer Biomet's return on equity of 12.73% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Zimmer Biomet11.86% 12.73% 7.34% Glaukos -21.43%-8.59%-6.61% Which has more risk & volatility, ZBH or GKOS? Zimmer Biomet has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. SummaryZimmer Biomet beats Glaukos on 9 of the 17 factors compared between the two stocks. Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GKOS vs. The Competition Export to ExcelMetricGlaukosMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$5.07B$6.80B$5.48B$20.71BDividend YieldN/A1.35%3.99%3.67%P/E Ratio-53.3424.4429.9428.65Price / Sales13.1654.22398.9469.00Price / CashN/A20.5535.9423.59Price / Book6.605.528.104.32Net Income-$146.37M$178.18M$3.26B$995.66M7 Day Performance1.87%-0.57%0.68%1.91%1 Month Performance-14.19%-5.36%2.46%-0.54%1 Year Performance-26.94%6.18%27.69%14.76% Glaukos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GKOSGlaukos4.0015 of 5 stars$88.01-0.5%$127.42+44.8%-24.1%$5.07B$383.48M-53.34780ZBHZimmer Biomet4.6624 of 5 stars$92.48+2.0%$111.39+20.5%-7.1%$18.30B$7.68B20.4617,000Positive NewsEarnings ReportAnalyst ForecastGap UpSNNSmith & Nephew SNATS2.4299 of 5 stars$30.79-0.1%$28.00-9.1%+21.3%$13.49B$5.81B14.2617,349Dividend CutGap UpSOLVSolventum1.4575 of 5 stars$73.24+2.1%$84.38+15.2%+28.8%$12.67B$8.31B33.9122,000News CoveragePositive NewsEarnings ReportPENPenumbra4.882 of 5 stars$240.71-0.9%$300.47+24.8%+46.7%$9.39B$1.19B64.024,500STVNStevanato Group2.1493 of 5 stars€25.58+1.8%N/A+23.3%€7.75B€1.19B50.165,521News CoverageAnalyst RevisionIRTCiRhythm Technologies1.8142 of 5 stars$164.98+0.0%$157.30-4.7%+135.0%$5.30B$591.84M-56.312,000Insider TradeBLCOBausch + Lomb3.1004 of 5 stars$13.76+1.9%$15.56+13.0%-10.0%$4.87B$4.89B-17.6413,500TMDXTransMedics Group2.6411 of 5 stars$128.50+6.6%$123.00-4.3%-20.4%$4.38B$531.29M66.58210SLNOSoleno Therapeutics4.5817 of 5 stars$84.12-2.2%$108.70+29.2%+79.0%$4.24BN/A-18.2130Earnings ReportAnalyst ForecastGap UpINSPInspire Medical Systems4.64 of 5 stars$130.79+3.7%$208.55+59.5%-59.1%$3.86B$840.11M60.271,246Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies ZBH Alternatives SNN Alternatives SOLV Alternatives PEN Alternatives STVN Alternatives IRTC Alternatives BLCO Alternatives TMDX Alternatives SLNO Alternatives INSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GKOS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.